Global Pharmaceutical Safety Scores Reveal Supply Risks
Most sampled nations score below 50% on safety controls, signaling potential risks for households using imported medicine.
Updated on Oct. 26, 2026 in Economic Indicators
Live Poll
Do you trust the current international regulatory standards to prevent counterfeit and unsafe medicines?
The U.S. Chamber of Commerce Global Innovation Policy Center released an index highlighting global vulnerabilities in pharmaceutical safety. The data shows that the majority of sampled economies score below 50% on safety and quality controls, signaling significant risks for global drug supplies.
Why it matters
Counterfeit and unsafe medications pose direct risks to health and household spending. With over 7,000 pharmaceutical crimes recorded in 2025, understanding these gaps helps households evaluate the security of their medical supply chains.
The average index score for the 12 sampled economies stands at 43.03%, with eight economies scoring below 50%. This comes as $30 billion is spent annually on counterfeit medicines, a market bolstered by over 7,000 recorded pharmaceutical crime incidents in 2025.
The players
Global Innovation Policy Center
An arm of the U.S. Chamber of Commerce that advocates for intellectual property rights and secure global trade practices.
Pharmaceutical Security Institute
A non-profit organization that monitors pharmaceutical crime incidents and tracks counterfeit trends globally.
The details
The index calculates safety based on four equally weighted factors, including the strength of regulatory controls for imported medical quality. While the United States leads with a 97.83% score on intellectual property protections, other nations struggle with enforcement and supply chain integrity. Counterfeit operations frequently rely on weak regulatory oversight to introduce imitation products into the global stream of commerce.
Timeline
The Pharmaceutical Security Institute tracked 7,000 pharmaceutical crime incidents in 2025.
The Global Innovation Policy Center released the index on October 26, 2026.
Money Landscape
The global pharmaceutical market faces rising security challenges, with annual spending on counterfeit goods reaching $30 billion. The new index highlights a persistent gap in regulatory controls, placing the issue of drug safety at the forefront of international trade policy discussions.
Households should be aware that counterfeit risks vary significantly by region and import source. Consult your healthcare provider or a licensed pharmacist to verify the origin and safety of medications if you rely on international suppliers.
The takeaway
Counterfeit drugs represent a substantial financial and health threat that is increasingly difficult to track. Households should prioritize sourcing medications through established, highly regulated domestic channels to avoid risks associated with unverified supply chains.
Further reading
For more on how global developments affect pricing and supply, explore our Economic Indicators section.
Source note: This article includes information reported by IPWatchdog.com | Patents & Patent Law.
Live Poll
Do you trust the current international regulatory standards to prevent counterfeit and unsafe medicines?
